ANTI-TUMOR ACTIVITY OF VELVANGA PARPAM (OFFICIAL SIDDHA DRUG) AGAINST DALTON'S ASCITES LYMPHOMA IN RODENTS

Benign prostatic hyperplasia (BPH) is a proliferation of nonmalignant stromal and epithelial cells in the prostate. BPH is the 5th most prevalent non-cancer-related disorder among men aged 50 years and older. The DAL (Dalton Ascitis Lymphoma) c ancer cell line proliferation in animal models to ascertain the efficacy of the interventional drug Velvanga parpam (VP) in the reduction of cell multiplication rate with respect to the prostatic hyperplasia. VP was evaluated for anti-tumor activity agains Swiss albino mice, administrated at the doses of 1.5 and 3 mg /kg body weight per day for 9 days. The present study deals with the effect of VP on the growth of solid tumor, life span of DAL profile. VP caused sign ificant decrease in tumor volume and it prolonged the life span of DAL-tumor bearing mice. Hematological profile converted to near normal levels in drug-treated mice. The Velvanga Parpam can be used as a novel potential agent for BPH, and the area of cance